The University of Texas MD Anderson Cancer Center

June 11, 2018

Amgen, MD Anderson Collaborate to Advance Early-stage Treatments for Myeloma, Other Cancers

News

Two multi-year collaborative agreements were recently established by Amgen and the University of Texas MD Anderson Cancer Center to advance the development of early-stage investigative therapies in Amgen’s portfolio ... Read more

April 29, 2016April 29, 2016

Protein Identified that May Point to Myeloma Patients Likely to Respond to Proteasome Inhibitors

News

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with other institutions, identified a gene called TJP1 that could help predict which multiple myeloma (MM) patients are ... Read more